ITE Live 2 (Diabetes, Lipids/Obesity, Reproduction)
ITE Live 2 (Diabetes, Lipids/Obesity, Reproduction)
Welcome to ITE Live 2021! There will be two webinars, intended to mimic the ITE Live session that occurs at the in-person ENDO each year. This course is for the second webinar, to take place on 5/19/2021, which will cover the Diabetes, Lipids/Obesity, and Reproduction questions from ITE 2021. The first webinar, to take place on 5/12, will cover the Adrenal, Pituitary, Bone, and Thyroid questions from ITE 2021.
Each webinar will have time reserved after each section for audience Q&A, and will be recorded and made available to all ITE 2021 participants.
Register today to participate in the ITE Live webinars!
This webinar will be of interest to fellows who participated in ITE 2021 and their program directors/associate program directors.
By the end of these webinars, fellows and their program directors will:
- Better understand some of the more complex questions from ESAP-ITE 2021;
- Identify important aspects of case-based questions seen in exams;
- Walk through the rationale for solving case-based care questions.
Darrick Beckman, MD
San Antonio Uniformed Health Services
Gunjan Gandhi, MD
University of Florida
Reshmi Srinath, MD
Icahn School of Medicine at Mount Sinai
Nicole Vietor, MD
Walter Reed National Military Medical Center
Alan Dalkin, MD
University of Virginia Health Center
Elaine Pelley, MD (2020-2021 Program Chair)
University of Wisconsin Hospital and Clinics
Salila Kurra, MD (2021-2022 Program Chair)
Columbia University Irving Medical Center
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s ITE Faculty Workgroup.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Elaine Pelley, MD; Salila Kurra, MD; Reshmi Srinath, MD; Nicole Vietor, MD; Alan Dalkin, MD; Gunjan Gandhi, MD
The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
USE OF PROFESSIONAL JUDGMENT:
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter.